Back to search results
NCT07361354

An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

Active, Not Recruiting
PHASE1Ages 18–65InterventionalTreatment
Angitia Incorporated Limited
~28 participants
Updated 2026-07-08 on ClinicalTrials.gov
What's tested:AGA2118

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum concentration (Cmax)
Measured over Day 1 to up to the end of study (85 days post-dose)
+5 more outcomes measured

Conditions

Healthy Participants
Pharmacokinetic Study

Explore related trials

Healthy Participants

Where it's being run

1 sites across 1 states
California1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Healthy males or females, aged 18 to 65 years
25-hydroxyvitamin D ≥30 ng/mL and agree to taking calcium and vitamin D supplements during the study
Meet the criteria for Japanese, Chinese, or Caucasian ethnicity

Exclusion

Participating or have participated in another clinical trial within the past 6 months
Any bone fracture within the past 6 months
History of myocardial infarction or stroke within the past 12 months
Malignancy within the past 5 years
Current hyper- or hypocalcemia
Pregnant or breastfeeding women, or women planning to become pregnant during the study

What this trial measures

  • Maximum concentration (Cmax)Day 1 to up to the end of study (85 days post-dose)

    Cmax of AGA2118 after dosing

  • Time to maximum concentration (Tmax)Day 1 to up to the end of study (85 days post-dose)

    Tmax of AGA2118 after dosing

  • Area under the concentration-time curve (AUC)Day 1 to up to the end of study (85 days post-dose)

    AUC of AGA2118 after dosing

  • Half-life (t1/2)Day 1 to up to the end of study (85 days post-dose)

    t1/2 of AGA2118 after dosing

  • Clearance (CL)Day 1 to up to the end of study (85 days post-dose)

    CL of AGA2118 after dosing

  • Volume of distribution (Vd)Day 1 to up to the end of study (85 days post-dose)

    Vd of AGA2118 after dosing